Abuse TobaccoNCT06868368
Perceptions of Vaping Products
A study testing Biospecimen Collection, Survey Administration and Vaping Topography in people with Abuse Tobacco and Exposure, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
Trial summary
This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults. Read more about this study
- Who is it for?
- Ages 21 to 34 yearsHealthy volunteers can take part
- Conditions the study is for
- Abuse Tobacco, Exposure
- What is being tested?
- Biospecimen Collection, Survey Administration and Vaping Topography
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 53 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Mar 2025to 4 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 34 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged 21-34 years
- Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
- Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
- Read and speak English
Who cannot join
- Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
- Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
- History of cardiac event or distress within the past 3 months
- Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
- Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
- Have hemophilia or another type of bleeding disorder
- Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
Trial locations and contacts
1 site in 1 country.
United States1 site
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
About this study
Official title: Perceptions of Vaping Products Among Young Adults
This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.
Read the detailed description
PRIMARY OBJECTIVES:
- Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.
II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.
III. Determine the impact of metatine on e-cigarette puffing behavior (topography).
OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.
- Conditions
- Abuse Tobacco, Exposure
- Being tested
- Biospecimen Collection, Survey Administration, Vaping Topography, Participant's Own Preferred E-cigarette, Nicotine E-cigarette
- Medical subject headings
- Tobacco Use Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionOther
Also called Biological Sample Collection
Undergo blood sample collection
Survey AdministrationOther
Complete Surveys
Vaping TopographyBehavioural
Use e-cigarette connected to a topography device
Participant's Own Preferred E-cigaretteOther
Participant vapes their own preferred e-cigarette for 30 minutes
Nicotine E-cigaretteOther
Participant vapes a commercially available nicotine e-cigarette for 30 minutes
6-methyl-nicotine (metatine) e-cigaretteOther
Participant vapes a commercially available metatine e-cigarette for 30 minutes
| Study group | Role | What they receive |
|---|---|---|
| Participant's personal nicotine e-cigarette | Active comparator | The study participant's own preferred e-cigarette will be used for this condition. Receives: Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: Participant's Own Preferred E-cigarette |
| Nicotine e-cigarette | Active comparator | A fruit flavored commercially available nicotine e-cigarette will be used for this condition. Receives: Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: Nicotine E-cigarette |
| 6-methyl nicotine (metatine) e-cigarette | Active comparator | A fruit flavored commercially available metatine e-cigarette will be used for this condition. Receives: Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: 6-methyl-nicotine (metatine) e-cigarette |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics of metatine and nicotine e-cigarettes
Pharmacokinetics of metatine and nicotine e-cigarettes will be examined by measuring the concentration of metatine and nicotine in blood plasma at different timepoints throughout the study vaping session.
Measured: Pre-vaping session, Minute 5 of vaping session, Minute 15 of vaping session, Minute 30 of vaping session
E-cigarette puffing behavior
E-cigarette puffing behavior will be measured with a topography device that records frequency, duration, and flow rate of e-cigarette puffs. These measures are combined to inform the overall measure of e-cigarette puffing behavior.
Measured: Week 1, Week 2, Week 3
Sensory perceptions of EC vaping experience
Sensory perceptions of vaping will be measured by the Sensory E-cigarette Expectancies Scale (SEES) questionnaire. The SEES asks questions about sensory experiences associated with vaping on a scale from 0 (Never) - 4 (Almost Always).
Measured: Minute 5 of vaping session, Minute 30 of vaping session
Appeal ratings
Participants will rate appeal (e.g., liking, disliking) on Visual Analogue Scales (range, 0-100).
Measured: Minute 5 of vaping session, Minute 30 of vaping session
Sensory ratings
Participants will rate sensory attributes (e.g., harshness, coolness) on Visual Analogue Scales (range, 0-100).
Measured: Minute 5 of vaping session, Minute 30 of vaping session
Relief of withdrawal symptoms
Nicotine withdrawal relief will be measured by the Minnesota Nicotine Withdraw Scale (MNWS). The MNWS asks users how much they are currently feeling certain nicotine withdraw symptoms on a scale of None, Slight, Moderate, Mild, or Severe.
Measured: Pre-vaping session, Minute 5 of Vaping Session, Minute 30 of vaping session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2025
- Study start3 Mar 2025
- Primary completion4 Nov 2025
- Study completion4 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abuse TobaccoStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomization to condition order will be completed prior to study Visit 1. Each participant will receive a randomized ordering developed using a random sequence generator.
- Masking
- None (open label)
- Enrolment
- 53 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alayna Tackett, Ohio State University Comprehensive Cancer Center
- Investigators
- Alayna P Tackett, PhD, Principal investigator, Ohio State University Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06868368
- Sponsor's protocol ID
- OSU-24276
- Other IDs
- NCI-2024-10267
- Status last verified
- Sep 2025
- First submitted
- 14 Jan 2025
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perceptions of Vaping Products Among Young Adults
- ClinicalTrials.gov ID
- NCT06868368
- Acronym / sponsor ID
- OSU-24276
- Conditions
- Abuse Tobacco, Exposure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 53 participants (actual)
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 3 Mar 2025 (actual)
- Primary completion
- 4 Nov 2025 (actual)
- Study completion
- 4 Nov 2025 (actual)
- First posted
- 10 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.
Detailed description
PRIMARY OBJECTIVES:
- Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.
II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.
III. Determine the impact of metatine on e-cigarette puffing behavior (topography).
OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Randomization to condition order will be completed prior to study Visit 1. Each participant will receive a randomized ordering developed using a random sequence generator.
| Arm | Type | Receives |
|---|---|---|
| Participant's personal nicotine e-cigarette | Active comparator | Other: Biospecimen Collection, Other: Survey Administration, Behavioral: Vaping Topography, Other: Participant's Own Preferred E-cigaretteThe study participant's own preferred e-cigarette will be used for this condition. |
| Nicotine e-cigarette | Active comparator | Other: Biospecimen Collection, Other: Survey Administration, Behavioral: Vaping Topography, Other: Nicotine E-cigaretteA fruit flavored commercially available nicotine e-cigarette will be used for this condition. |
| 6-methyl nicotine (metatine) e-cigarette | Active comparator | Other: Biospecimen Collection, Other: Survey Administration, Behavioral: Vaping Topography, Other: 6-methyl-nicotine (metatine) e-cigaretteA fruit flavored commercially available metatine e-cigarette will be used for this condition. |
Who may qualify
- Ages
- 21 to 34 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Aged 21-34 years
- Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
- Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
- Read and speak English
Key exclusion criteria (7 listed)
- Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
- Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
- History of cardiac event or distress within the past 3 months
- Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
- Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample CollectionUndergo blood sample collection | Other | 6-methyl nicotine (metatine) e-cigarette, Nicotine e-cigarette, Participant's personal nicotine e-cigarette |
| Survey AdministrationComplete Surveys | Other | 6-methyl nicotine (metatine) e-cigarette, Nicotine e-cigarette, Participant's personal nicotine e-cigarette |
| Vaping TopographyUse e-cigarette connected to a topography device | Behavioural | 6-methyl nicotine (metatine) e-cigarette, Nicotine e-cigarette, Participant's personal nicotine e-cigarette |
| Participant's Own Preferred E-cigaretteParticipant vapes their own preferred e-cigarette for 30 minutes | Other | Participant's personal nicotine e-cigarette |
| Nicotine E-cigaretteParticipant vapes a commercially available nicotine e-cigarette for 30 minutes | Other | Nicotine e-cigarette |
| 6-methyl-nicotine (metatine) e-cigaretteParticipant vapes a commercially available metatine e-cigarette for 30 minutes | Other | 6-methyl nicotine (metatine) e-cigarette |
Primary outcome
Pharmacokinetics of metatine and nicotine e-cigarettes
Time frame: Pre-vaping session, Minute 5 of vaping session, Minute 15 of vaping session, Minute 30 of vaping session
Pharmacokinetics of metatine and nicotine e-cigarettes will be examined by measuring the concentration of metatine and nicotine in blood plasma at different timepoints throughout the study vaping session.
E-cigarette puffing behavior
Time frame: Week 1, Week 2, Week 3
E-cigarette puffing behavior will be measured with a topography device that records frequency, duration, and flow rate of e-cigarette puffs. These measures are combined to inform the overall measure of e-cigarette puffing behavior.
Sensory perceptions of EC vaping experience
Time frame: Minute 5 of vaping session, Minute 30 of vaping session
Sensory perceptions of vaping will be measured by the Sensory E-cigarette Expectancies Scale (SEES) questionnaire. The SEES asks questions about sensory experiences associated with vaping on a scale from 0 (Never) - 4 (Almost Always).
Appeal ratings
Time frame: Minute 5 of vaping session, Minute 30 of vaping session
Participants will rate appeal (e.g., liking, disliking) on Visual Analogue Scales (range, 0-100).
Sensory ratings
Time frame: Minute 5 of vaping session, Minute 30 of vaping session
Participants will rate sensory attributes (e.g., harshness, coolness) on Visual Analogue Scales (range, 0-100).
Relief of withdrawal symptoms
Time frame: Pre-vaping session, Minute 5 of Vaping Session, Minute 30 of vaping session
Nicotine withdrawal relief will be measured by the Minnesota Nicotine Withdraw Scale (MNWS). The MNWS asks users how much they are currently feeling certain nicotine withdraw symptoms on a scale of None, Slight, Moderate, Mild, or Severe.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- The JameslineLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Abuse Tobacco
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Recruiting
Developing an E-Cigarette Cessation Intervention for Hispanic/Latina(o) Youth in Florida: The BReATHE Study
Vaping Teens, Vaping Behaviors
Recruiting
Project Q: Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly or Non-daily
Tobacco Use Disorder
Not yet recruiting
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
Smoking Behaviors, Smoking ( Cigarette)
Recruiting
Use of Nicotine Pouches Among Daily Smokers
Tobacco Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alayna P Tackett, PhD principal investigator
Ohio State University Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biospecimen Collection, Survey Administration and Vaping Topography in people with Abuse Tobacco and Exposure, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics of metatine and nicotine e-cigarettes (time frame: Pre-vaping session, Minute 5 of vaping session, Minute 15 of vaping session, Minute 30 of vaping session). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.